Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and WORK Medical Technology Group (NASDAQ:WOK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Profitability
This table compares Pulse Biosciences and WORK Medical Technology Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | N/A | -73.77% | -63.98% |
| WORK Medical Technology Group | N/A | N/A | N/A |
Valuation & Earnings
This table compares Pulse Biosciences and WORK Medical Technology Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 3,995.87 | -$72.78 million | ($1.08) | -19.05 |
| WORK Medical Technology Group | $9.81 million | 0.00 | -$1.07 million | N/A | N/A |
WORK Medical Technology Group has higher revenue and earnings than Pulse Biosciences.
Insider & Institutional Ownership
77.0% of Pulse Biosciences shares are held by institutional investors. 74.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Pulse Biosciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, WORK Medical Technology Group has a beta of 3.51, suggesting that its stock price is 251% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Pulse Biosciences and WORK Medical Technology Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 2 | 0 | 2.33 |
| WORK Medical Technology Group | 1 | 0 | 0 | 0 | 1.00 |
Pulse Biosciences presently has a consensus target price of $30.00, suggesting a potential upside of 45.84%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Pulse Biosciences is more favorable than WORK Medical Technology Group.
Summary
Pulse Biosciences beats WORK Medical Technology Group on 6 of the 11 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About WORK Medical Technology Group
WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
